Clinical Trials Browser

OTHER × Afatinib × Thoracic × Clear all

NCT06897735 2025-11-18

EDDIS-a1

Phase 1 Not yet recruiting

DermatologicHead & NeckThoracic

Lung Neoplasms, Melanoma, Mouth Neoplasms

NCT04497584 2025-10-01

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Phase 2 Active not recruiting

Advanced Squamous Non Small Cell Lung Cancer

NCT05215548 2025-02-19

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Phase 2 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01553942 2024-11-20

Afatinib With CT and RT for EGFR-Mutant NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Phase 1 Completed

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04909073 2024-05-17

Observational Study of Afatinib 30 mg Daily

Carcinoma, Non-Small-Cell Lung

NCT01542437 2024-02-06

NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02768337 2024-01-31

CamBMT1

Phase 1/2 Terminated

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02183883 2023-11-29

DARWIN1

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04201756 2022-12-23

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Phase 2 Completed

Adenocarcinoma of Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03711422 2022-06-14

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms

NCT03054038 2022-04-14

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02629523 2021-08-03

LiquidLung-A

Phase 2 Completed

Lung Neoplasms

NCT04814056 2021-04-01

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Phase 4 Unknown

NRG1-fused Non-small Cell Lung Cancer

NCT04640870 2020-12-23

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Carcinoma, Non-Small-Cell Lung

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT04575415 2020-10-20

BELLA

NSCLC

NCT01746251 2020-07-07

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Phase 2 Terminated

2 enrolled 8 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02595840 2019-04-19

Trans-MARBLE

Phase 2 Terminated

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT02145637 2019-03-29

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Lung Neoplasms, Neoplasms

NCT03810872 2019-01-22

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Phase 2 Unknown

SarcomaThoracic

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01074177 2018-03-09

Understanding Mechanisms of Acquired Resistance to BIBW2992

Phase NA Completed

24 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02488694 2018-01-09

MARBLE

Phase 2 Terminated

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT02876081 2017-09-11

THEN

Phase 2 Withdrawn

Small Cell Lung Carcinoma

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Phase 1/2 Unknown

NSCLC

NCT01836341 2013-12-19

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01480141 2013-03-26

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Lung Neoplasms

NCT01776684 2013-01-28

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Phase NA Unknown

EGFR Mutation Positive Non-small Cell Lung Cancer